Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2013-04-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-psychotic Medication (Stable Dose) Weight Loss Study
NCT01272765
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
NCT01052714
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
NCT02796144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Group
Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
IHBG-10
500 mg IHBG-10
Control Group
Subjects will take a placebo 15 minutes prior to the three main meals of the day.
Placebo
Placebo taken 15 minutes prior to the three main meals of the day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IHBG-10
500 mg IHBG-10
Placebo
Placebo taken 15 minutes prior to the three main meals of the day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agree to keep diet, exercise and all current health habits stable during participation in the study
* Have been taking Risperdal (Risperidone), Seroquel (Quetiapine), or Zyprexa (Olanzapine) for less than 3 months
Exclusion Criteria
* Women who are pregnant, breastfeeding or planning to become pregnant
* Prior bariatric surgery
* Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
* Obesity as a result of a clinically-diagnosed endocrine problem
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avera McKennan Hospital & University Health Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy Soundy, MD
Role: PRINCIPAL_INVESTIGATOR
Avera McKennan Hospital & University Health Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Avera Research Institute
Sioux Falls, South Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARI-1310-IHBG10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.